Denali Therapeutics (DNLI) EBT (2017 - 2024)
Historic EBT for Denali Therapeutics (DNLI) over the last 8 years, with Q4 2024 value amounting to -$114.7 million.
- Denali Therapeutics' EBT rose 398.35% to -$114.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$422.7 million, marking a year-over-year decrease of 19113.12%. This contributed to the annual value of -$422.7 million for FY2024, which is 19113.12% down from last year.
- Latest data reveals that Denali Therapeutics reported EBT of -$114.7 million as of Q4 2024, which was up 398.35% from -$107.2 million recorded in Q3 2024.
- Over the past 5 years, Denali Therapeutics' EBT peaked at $245.7 million during Q4 2020, and registered a low of -$119.4 million during Q4 2023.
- For the 5-year period, Denali Therapeutics' EBT averaged around -$55.7 million, with its median value being -$80.2 million (2021).
- As far as peak fluctuations go, Denali Therapeutics' EBT soared by 55543.65% in 2020, and later tumbled by 15399.96% in 2024.
- Denali Therapeutics' EBT (Quarter) stood at $245.7 million in 2020, then plummeted by 130.86% to -$75.8 million in 2021, then crashed by 30.13% to -$98.7 million in 2022, then fell by 21.04% to -$119.4 million in 2023, then increased by 3.98% to -$114.7 million in 2024.
- Its EBT stands at -$114.7 million for Q4 2024, versus -$107.2 million for Q3 2024 and -$99.0 million for Q2 2024.